| Patient | Evel Knievel |
|---|---|
| Date of birth | 1968-10-17 |
| Identifiers | MRN HR-RB001-SYN; SSN (made up) 000-01-4927 |
| Document date | 2026-02-23 |
| Author | Dale Rasmussen, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
First day of hepatitis C treatment. [S]
Mr. Knievel returns four weeks after the hepatology visit to start sofosbuvir-velpatasvir, which has been approved. He takes carvedilol 6.25 mg daily without dizziness. He has had one drink in the past month and wants to stop altogether. He started aquatic therapy three weeks ago and walks a little farther; pain is about 5 of 10. He has taken no omeprazole, ibuprofen or herbal products. He has had no low glucose readings, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Today | Day 1 of 12 weeks of sofosbuvir-velpatasvir |
| Carvedilol | 6.25 mg daily; pulse 68, blood pressure 128/78 |
| Alcohol | One drink in the past month |
| Pain | 5 of 10 with aquatic therapy |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Still tired in the afternoons; no fever |
| Gastrointestinal | Negative | No abdominal swelling, black stools or heartburn |
| Cardiovascular | Negative | No dizziness on standing |
| Musculoskeletal | Positive | Hip and knee pain, 5 of 10; no muscle aches |
| Endocrine | Negative | No shakiness or sweating to suggest low glucose |
| Psychiatric | Negative | Mood steady; PHQ-9 5; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet twice daily with breakfast and supper | Oral route | 2021-03-01 | active | S |
| Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back pain | One tablet three times a day | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofen | One capsule daily before breakfast | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day | Two tablets up to twice a day as needed; no more than 2 g a day | Oral route | 2026-01-12 | active | S |
| Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day | 4 g to each knee up to four times a day | Topical route | 2026-01-12 | active | S |
| Carvedilol 6.25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 to 2026-02-23 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 | active | S |
| Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeks | One tablet daily for 12 weeks | Oral route | 2026-02-23 to 2026-05-17 | completed | S |
| Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-02-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-23 | Body height | 178 | cm | S |
| 2026-02-23 | Body weight | 84.8 | kg | S |
| 2026-02-23 | Body mass index (BMI) [Ratio] | 26.8 | kg/m2 | S |
| 2026-02-23 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-02-23 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-23 | Heart rate | 68 | /min | S |
| 2026-02-23 | Respiratory rate | 14 | /min | S |
| 2026-02-23 | Body temperature | 36.6 | Cel | S |
| 2026-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-23 | Hemoglobin [Mass/volume] in Blood | 14 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-02-23 | Leukocytes [#/volume] in Blood by Automated count | 4.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-02-23 | Platelets [#/volume] in Blood by Automated count | 121 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-02-23 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 100 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-23 | Glucose [Mass/volume] in Serum or Plasma | 141 | mg/dL | 70-99 mg/dL | High | S |
| 2026-02-23 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 81 | U/L | 7-55 U/L | High | S |
| 2026-02-23 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 90 | U/L | 8-48 U/L | High | S |
| 2026-02-23 | Bilirubin.total [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-23 | Albumin [Mass/volume] in Serum or Plasma | 3.7 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-23 | Calcium [Mass/volume] in Serum or Plasma | 9.1 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-02-23 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 17 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-02-23 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 388 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-23 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-02-23 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-02-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-02-23 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S |
Vital signs recorded on 2026-02-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 84.8 kg; blood pressure 128/78, pulse 68 |
| Skin | Spider angiomas unchanged; no jaundice or bruising |
| Abdomen | Spleen tip palpable; no ascites |
| Musculoskeletal | Reduced hip rotation; knee crepitus; old forearm fracture deformities |
| Neurological | No asterixis |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered | resolved | confirmed | R74.01 | S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation. |
| Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis C | active | confirmed | B18.2 | S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D). |
| Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleeding | active | confirmed | K74.69 | S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant. |
| Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII) | active | confirmed | K76.6 | S — Synthetic finding at the hepatology consultation. |
| Type 2 diabetes on metformin, A1c 7.4% | active | confirmed | E11.65 | S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice. |
| Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids | active | confirmed | G89.29 | S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding before the bone density scan. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count, hepatic function panel and eGFR | Within three months before HCV treatment | Completed today | Hemoglobin 14.0 g/dL, white cells 4.8, platelets 121; creatinine 0.90 mg/dL, eGFR 100; ALT 81, AST 90 U/L, bilirubin 1.0 mg/dL, albumin 3.7 g/dL |
| Laboratory | INR | Within three months before HCV treatment | Up to date | 1.1 in January |
| Medication safety | Drug interaction review | At the start of HCV treatment | Completed today | No proton pump inhibitor, amiodarone or supplements; atorvastatin with muscle-pain monitoring |
| Medication safety | Hypoglycemia monitoring on diabetes medicine during HCV treatment | Throughout treatment | Completed today | Sensor started; he knows how to treat a low |
| Medication safety | Carvedilol titration | Every two to four weeks to the target dose | Completed today | Raised to 12.5 mg daily; pulse 68, blood pressure 128/78 |
| Medication safety | Hepatitis B vaccination, dose 2 | One month after dose 1 | Completed today | Given today; series complete |
| Laboratory | Vitamin D, calcium and TSH (secondary causes of bone loss) | Before bone density testing in a man at risk | Completed today | Vitamin D 17 ng/mL (low); calcium 9.1 mg/dL; TSH 2.1 |
| Laboratory | Vitamin B12 on long-term metformin | Periodically | Completed today | 388 pg/mL, normal |
| Imaging | Bone density (DXA) | Men at risk: cirrhosis, alcohol and prior fractures | Ordered | Booked in two weeks |
| Referral | Physical therapy | For falls and chronic pain | Up to date | Assessed three weeks ago; aquatic therapy twice a week |
| Referral | Diabetic eye examination | Yearly | Referred | Referral made at the last visit; not yet booked |
| Examination | Signs of decompensation (ascites, encephalopathy, jaundice, bleeding) | Each visit in cirrhosis | Completed today | None |
| Survey | Alcohol use (AUDIT-C) | Each visit in liver disease | Completed today | AUDIT-C 1; he plans to stop |
| Survey | Pain score and function | Each visit | Completed today | 5 of 10; walking farther |
| Survey | Depression screen (PHQ-9) | At diagnosis and when treatment changes | Completed today | PHQ-9 5 |
Goal progress:
Immunizations given today: Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 2 of 2 [S]
Guideline basis: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025); de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021); Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Bone density scan in two weeks. Review at the end of 12 weeks of treatment. Call for jaundice, dark urine, abdominal swelling, black stools, confusion, faintness or low glucose readings. Next scheduled visit 2026-05-18: end of 12 weeks of antiviral treatment: liver tests, glucose monitoring in cirrhosis, osteoporosis, pain, and abstinence. [S]